Last reviewed · How we verify
mFOLFOX6-bevacizumab
mFOLFOX6-bevacizumab is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin with bevacizumab, an anti-angiogenic monoclonal antibody.
mFOLFOX6-bevacizumab is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin with bevacizumab, an anti-angiogenic monoclonal antibody. Used for Metastatic colorectal cancer.
At a glance
| Generic name | mFOLFOX6-bevacizumab |
|---|---|
| Sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group |
| Drug class | chemotherapy regimen |
| Target | VEGF |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The oxaliplatin, 5-fluorouracil, and leucovorin combination works by interfering with DNA replication and cell division, while bevacizumab targets vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis.
Approved indications
- Metastatic colorectal cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Neutropenia
- Vomiting
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (PHASE2)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (PHASE3)
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (PHASE3)
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors (PHASE1, PHASE2)
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (EARLY_PHASE1)
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) (PHASE3)
- Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mFOLFOX6-bevacizumab CI brief — competitive landscape report
- mFOLFOX6-bevacizumab updates RSS · CI watch RSS
- GERCOR - Multidisciplinary Oncology Cooperative Group portfolio CI